CiplaCPLFY 94 Receivables Turnover is 1.15 as of Mar. 2026. GuruFocus rates CPLFY with a GF Score™ of 94/100. The stock has 6 warning signs investors should review. Among 947 Drug Manufacturers companies, Cipla ranks worse than 56.28% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cipla's Revenue for the
three
months ended in Mar. 2026 was $696.44 Mil. Cipla's average Accounts Receivable for the
three
months ended in Mar. 2026 was $605.49 Mil.
Hence, Cipla's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.15.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cipla Receivables Turnover Related Terms
Cipla Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cipla's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPLFY vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cipla's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipla (CPLFY) has a Receivables Turnover of 1.15 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cipla and its competitors. According to the industry distribution chart, Cipla ranks #533 out of 947 companies in the Drug Manufacturers industry, placing it in the top 56.3%.
Is Cipla's Receivables Turnover too high?
Cipla's current Receivables Turnover is 1.15. The Drug Manufacturers industry median Receivables Turnover is 5.07. Cipla's value of 1.15 is 77.3% below this industry median. Based on the distribution chart, Cipla ranks #533 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #533 out of 947 companies for Receivables Turnover. This places Cipla in the lower half of its industry. The industry median Receivables Turnover is 5.07. Cipla's value of 1.15 is 77.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current Receivables Turnover of 1.15 is 77.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current Receivables Turnover is 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current Receivables Turnover of 1.15. The current Receivables Turnover is 1.15 and 77.3% below the Drug Manufacturers industry median of 5.07. Cipla's overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cipla (CPLFY), the current Receivables Turnover is 1.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPLFY has been successfully added to your 